ABSTRACT

Rituximab is popularly used in the treatment of B-cell lymphomas that bear CD20 antigen. Most of the adverse events (AEs) induced by rituximab are infusion-related symptoms. However, rituximab-induced acute thrombocytopenia (RIAT), which often develops within the 1–3 days after rituximab administration, is relatively unusual, severe, and usually self-recovering. Until now, most of the reports about RIAT were described as case reports and RIAT often occurred in patients with mantle cell lymphoma (MCL). Here, we report two patients who developed severe RIAT, one patient had a refractory and relapsed follicular lymphoma (FL), and the other patient was newly diagnosed with splenic marginal zone lymphoma (SMZL). RIAT is a rare, under-diagnosed but serious adverse event that should arouse attention to clinicians, and routine blood count monitoring should be considered after the administration of rituximab, especially for high-risk lymphoma patients or patient with splenomegaly.

摘要

利妥昔单抗广泛用于治疗携带 CD20 抗原的 B 细胞淋巴瘤。大多数由利妥昔单抗引起的不良事件 (AE) 是输注相关症状。然而，利妥昔单抗引起的急性血小板减少症 (RIAT) 通常在利妥昔单抗给药后 1-3 天内发生，相对少见、严重且通常可自行恢复。迄今为止，大多数关于 RIAT 的报告都被描述为病例报告，并且 RIAT 经常发生在套细胞淋巴瘤 (MCL) 患者中。在这里，我们报告了两名发生严重 RIAT 的患者，一名患者患有难治性和复发性滤泡性淋巴瘤 (FL)，另一名患者新诊断为脾边缘区淋巴瘤 (SMZL)。RIAT 是一种罕见的、诊断不足但严重的不良事件，应引起临床医生的注意，